An introduction to assessing genomic screening and diagnostic tests

Nutrition Today

Volumn 46, Issue 4, 2011, Pages 162-168

  Haddow, James E ^a   Palomaki, Glenn E ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80051706705     PISSN: 0029666X     EISSN: 15389839     Source Type: Journal    
DOI: 10.1097/NT.0b013e3182261d7f     Document Type: Review

References (14)

1. Paynter NP, Chasman DI, Pare G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631-637.
2. Haddow JE, Palomaki GE: ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Oxford: Oxford University Press; 2003:217-233.
3. Wald N, Cuckle H. Reporting the assessment of screening and diagnostic tests. Br J Obstet Gynaecol. 1989;96:389-396.
4. Enhancing the oversight of genetic tests: Recommendations of the SACGT. July 2000. http://oba.od.nih.gov/oba/ sacgt/reports/oversight-report.pdf. Accessed February 23, 2010.
5. McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: Public health implications. Genet Med. 2005;7:28-33. (Pubitemid 40111128)
6. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group. Genet Med. 2009;11:3-14.
7. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med. 2009;11:15-20.
8. Recommendations from the EGAPP Working Group: Can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med. 2009;11:66-73.
9. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11:35-41.
10. Recommendations from the EGAPP Working Group: Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9:819-825.
11. Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease: A meta-analysis. JAMA. 2010;303:648-656.
12. Wald NJ, Morris JK, Rish S. The efficacy of combining several risk factors as a screening test. J Med Screen. 2005; 12:197-201. (Pubitemid 43843295)
13. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ. 1999;319: 1562-1565.
14. Gudgeon JM, Palomaki GE, Williams MS. Rapid, evidence-based reviews of genetic tests. In: Khoury MJ, Bedrosian SR, Gwinn M, Higgins JPT, Ioannidis JPA, Little J, eds. In: Human Genome Epidemiology. New York: Oxford University Press; 2010:482-496.